Stay updated on Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0 and now includes 2 locations, replacing the previous version v2.9.7.
    Difference
    0.2%
    Check dated 2024-07-23T15:05:07.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T08:03:37.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T14:15:11.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-27T10:07:38.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content version.
    Difference
    0.1%
    Check dated 2024-06-26T08:53:32.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Drug Information available for: Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Single Arm Assignment Pembrolizumab + External Beam Radiation Therapy Drug : Pembrolizumab 200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered. Other Names: Keytruda Radiation : External Beam Radiation Therapy 20-30 Gy over five fractions for up to two cycles.' This change represents an update in the drug information and study details related to the use of Pembrolizumab in combination with External Beam Radiation Therapy for the treatment of Carcinoma of Unknown Primary (CUP) patients.
    Difference
    28%
    Check dated 2024-06-25T08:31:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.